QPPV.COM KNOWLEDGE ASSESSMENT

Tezacaftor: Discovery, Development, Safety and Pharmacovigilance

Test your understanding of the concepts covered by Tezacaftor: Discovery, Development, Safety and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Why is a newly started azole antifungal relevant when investigating abnormal liver tests in a patient on a CFTR modulator?
Question 2 of 10 Which statement best reflects the interpretation of limited pregnancy or breastfeeding data?
Question 3 of 10 What question did the EXPAND comparison of tezacaftor/ivacaftor with ivacaftor alone particularly help address?
Question 4 of 10 A patient on a CFTR modulator develops raised transaminases. Which case information would most improve medical assessment?
Question 5 of 10 Which statement best describes the role of signal detection in pharmacovigilance?
Question 6 of 10 A patient has an unexpected lack of treatment effect on a tezacaftor-containing regimen. Which assessment is most consistent with the article's approach?
Question 7 of 10 A patient taking a tezacaftor-containing regimen starts a strong CYP3A inhibitor. What is the most appropriate medication-safety response?
Question 8 of 10 Why should the EXPAND results not be generalized to every patient described as having a residual-function mutation?
Question 9 of 10 What is the most defensible interpretation of the clinical efficacy evidence for tezacaftor-containing treatment?
Question 10 of 10 A company reports strong commercial performance for a triple combination containing tezacaftor. What is the appropriate pharmacological interpretation?

Select an answer to continue.

QPPV.com